ClinicalTrials.gg
CompletedNCT06152900Updated Dec 1, 2023

Safety and Efficacy of Electronic Stimulation for Circumferential Reduction and Muscle Toning

An interventional study of Accufit in Fat Necrosis and Muscle Stimulation, sponsored by LUTRONIC Corporation. Completed at 2 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-12-01.

Sponsored by LUTRONIC Corporation (part of Cynosure Lutronic, Inc.) · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Nov 2022, 3 years 11 months ago, and no results have been posted to the registry.
  • Registered 2 years 1 month after the study started (first participant enrolled Oct 2021, registered Nov 2023).
Phase
Not applicable
Study type
Interventional
Enrollment
45
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Open-label, baseline-controlled, multi-center study evaluating an electrical muscle stimulation system for circumferential reduction and muscle toning. The study will enroll up to 100 subjects desiring circumferential reduction and muscle toning. Each subject will receive up to 12 bi-weekly treatments over a 6-week period. Follow Up Visits planned for 2, 30- and 90-days post treatment. Measurement outcomes will be compared to baseline.

02

Conditions studied

  • Fat Necrosis
  • Muscle Stimulation
03

In context

Lead sponsor

LUTRONIC Corporation is the lead sponsor of 13 studies on the registry; 1 is open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.

First submitted before LUTRONIC Corporation became part of Cynosure Lutronic, Inc..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able to read, understand and voluntarily provide written .
  2. Healthy male or female, ≥ 18 years to 65 years of age seeking treatment for improved muscle strength and muscle toning in their core and extremities.
  3. Subject is determined to be physically fit and agrees to not making any major changes in their diet or lifestyle during the study.
  4. Able and willing to comply with the treatment/follow-up schedule and requirements.
  5. Women of child-bearing age are required to be using a reliable method of at least 3 months prior to study enrollment and for the duration of the study as well as have a negative Urine Pregnancy test at baseline.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant in the last 3 months, intending to become pregnant, postpartum or nursing in the last 6 months.
  2. Any previous liposuction/lipo-sculpture or any type of surgical procedure in the treatment area in the past 12 months.
  3. History of /immune deficiency disorders (including AIDS and infection) or use of immunosuppressive medications, 6 months prior to and during the study.
  4. History of hyperlipidemia, diabetes mellitus, hepatitis, blood coagulopathy or excessive bleeding.
  5. Having a history of skin cancer or any other cancer in the areas to be treated, including presence of malignant or premalignant pigmented lesions.
  6. Having a permanent implant in the treatment area such as metal plates or an injected chemical substance such as silicone in the treatment area.
  7. Suffering from significant skin conditions in the treatment area or inflammatory skin conditions including but not limited to open lacerations, abrasions, herpes sores, cold sores, active infections.
  8. Poor skin quality (severe laxity).
  9. Abdominal wall, muscular abnormality or hernia on physical examination.
  10. As per the investigator's discretion, any physical or mental condition which may make it unsafe for the subject to participate.
  11. Subjects unwilling or unable to adhere to all study requirements for treatment and follow-up.
  12. Investigator may exclude any subject at any time at his/her discretion.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    Treatment Arm

    All subjects enrolled in the study will be placed into the treatment arm of the study, to be treated by the Accufit device.

    Device: Accufit

Interventions

  • DeviceAccufit

    Magnet-based and Direct muscle stimulation devices are commonly used to generate current flow through the muscles in order to activate the muscle. The Accufit Electrical Muscle Stimulation device is an FDA cleared device having a two-channel stimulator that provides up to 8 electrodes with waveforms of interferential and biphasic for muscle stimulation. The Accufit system is indicated for relaxation of muscles, muscle re-education, reduction of pain and increased local blood circulation. Muscle stimulation technology has been around for many decades and has been shown to be safe and effective for a variety of clinical applications. The foundational basis for the technology revolves around electrical current flowing through the muscle can be used to activate the muscle.

    Also known as: ME Sys*STIM 240

06

What researchers measure

Primary outcomes

  1. Photographic Evaluation

    Photographic evaluation by an independent, blinded reviewer with correct identification of pre-treatment baseline images when compared to post-treatment images taken at follow up visits (48 hours, 30 days, 90 days).Results will be reported as a % of the correctly identified post treatment photographs chosen per Blinded Reviewer. An average of the % of the correctly identified post treatment photographs chosen by Blinded Reviewer will be calculated and used to determine efficacy.

    Time frame: Baseline, 48-hours post treatment, 30-day FU, 90-day FU

Secondary outcomes

  1. Circumferential Reduction

    Reduction in circumference as measured by Seca Circumferential System at follow up visits compared to baseline measurement. Measurements were taken of the right and left arm in both a relaxed and engaged position.

    Time frame: Baseline, 30-day FU, 90-day FU

  2. Subject Satisfaction

    Assess subject satisfaction using Satisfaction survey at each follow up visit. Scores available in the scale include the following: 1. - Very Satisfied 2. - Satisfied 3. - Neutral 4. - Dissatisfied

    Time frame: 30-day FU, 90-day FU

  3. Global Aesthetic Improvement Scale

    A scale to assess the overall improvement in a subject's condition in an unblinded fashion. Choices on the scale include the following: 1. - Very Much Improved 2. - very Improved 3. - Improved 4. - No Change 5. - Worsened

    Time frame: 30-day FU, 90-day FU

  4. Muscle Strength

    Improvement in muscle strength of the treated extremity as measured by a dynamometer at follow up visits compared to baseline measurements. Subjects are asked to hold onto a handheld device which will then be used to measure the strength of the bicep and tricep muscles.

    Time frame: Baseline, 30-day FU, 90-day FU

07

Study locations

2 sites
  • Lutronic US Headquarters
    Billerica, Massachusetts 01821, United States
  • Union Square Dermatology
    New York, New York 10003, United States
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — No IPD Sharing planned at this time.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 1, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06152900
Responsible party
Sponsor
First posted
Dec 1, 2023
Start date
Oct 5, 2021
Primary completion
Nov 20, 2022
Completion
Nov 20, 2023
Last update
Dec 1, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion